Zanubrutinib

Brukinsa (zanubrutinib) is approved in the Russia to treat patients with relapsed or refractory mantle cell lymphoma (MCL)

CAMBRIDGE, Mass. & BEIJING & MOSCOW October 20, 2021  The Russia Ministry of Health has approved BeiGene’s Brukinsa (zanubrutinib) to treat patients with relapsed or refractory mantle cell lymphoma (MCL). Marketing approval for BRUKINSA for the treatment of MCL in Russia is based on results from two single-arm clinical trials.…